Update to Institutional Equity Analyst

{
  "description": "Use to map industry structure, value chain, market size, competition, technology transitions, and leading indicators. Produces a source-traceable workflow with deterministic calculations, explicit open gates, and an auditable decision layer.",
  "included_files": [
    {
      "relative_path": "agents/openai.yaml",
      "size_in_bytes": 207
    }
  ],
  "name": "industry-map",
  "skill_md_contents": "---\r\nname: industry-map\r\ndescription: Use to map industry structure, value chain, market size, competition, technology transitions, and leading indicators. Produces a source-traceable workflow with deterministic calculations, explicit open gates, and an auditable decision layer.\r\n---\r\n\r\n# Industry Map\r\n\r\nUse this workflow only when it matches the user's requested scope. The original manual in ../../canonical is authoritative and must not be condensed away.\r\n\r\n## Read first\r\n\r\n- ../../references/v2/source-policy.md\r\n- ../../references/v2/evidence-system.md\r\n- ../../references/v2/state-and-gates.md\r\n- ../../references/v2/audit-protocol.md\r\n- ../../references/v2/confidence-scoring.md when scoring confidence\r\n- ../../references/v2/research-budget-evoi.md for deep prioritization\r\n\r\n## Canonical routing\r\n\r\n- M031-M035\r\n- Master Lab 05\r\n\r\n## Required workflow gates\r\n\r\n1. market boundary\r\n2. value chain and profit pools\r\n3. bottom-up TAM\r\n4. competitor normalization\r\n5. technology and substitution\r\n6. leading indicators\r\n7. falsification\r\n\r\nUse the schemas in ../../schemas/v2, applicable deterministic scripts in ../../scripts, and the relevant sector model in ../../sector-models. For a current company, browsing and primary-source retrieval are mandatory. Classify each material statement, retain contrary evidence, and state the research cutoff. Run ../../scripts/research_audit.py before a completion claim. Failed mandatory gates require RESEARCH INCOMPLETE, with the missing evidence and decision impact named explicitly.\r\n\r\nDo not execute securities transactions or present research confidence as a guarantee of investment outcome.\r\n"
}